Edited by: Michael Wechsler
An assay that may predict the development of IgG enhancing allergen-specific IgE binding during birch immunotherapy
Article first published online: 3 SEP 2013
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
Volume 68, Issue 9, pages 1199–1202, September 2013
How to Cite
An assay that may predict the development of IgG enhancing allergen-specific IgE binding during birch immunotherapy. Allergy 2013; 68: 1199–1202., , , , .
- Issue published online: 18 SEP 2013
- Article first published online: 3 SEP 2013
- Manuscript Accepted: 9 MAY 2013
- Austrian Science Fund (FWF). Grant Numbers: F4602, F4604, F4613
- Bet v 1;
- birch pollen allergy;
- enhancing IgG antibodies;
- recombinant allergen
It has been shown that birch pollen immunotherapy can induce IgG antibodies which enhance IgE binding to Bet v 1. We aimed to develop a serological assay to predict the development of antibodies which enhance IgE binding to Bet v 1 during immunotherapy.
In 18 patients treated by Bet v 1-fragment-specific immunotherapy, the effects of IgG antibodies specific for the fragments on the binding of IgE antibodies to Bet v 1 were measured by ELISA. Blocking and possible enhancing effects on IgE binding were compared with skin sensitivity to Bet v 1 after treatment.
We found that fragment-specific IgG enhanced IgE binding to Bet v 1 in two patients who also showed an increase of skin sensitivity to Bet v 1.
Our results indicate that it may be possible to develop serological tests which predict the induction of unfavourable IgG antibodies enhancing the binding of IgE to Bet v 1 during immunotherapy.